{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:00:07Z","timestamp":1779908407088,"version":"3.53.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.pupt.2023.102229","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T20:31:48Z","timestamp":1687465908000},"page":"102229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Preventive effect of LCZ696 on hypoxic pulmonary hypertension in rats via regulating the PI3K\/AKT signaling pathway"],"prefix":"10.1016","volume":"82","author":[{"given":"Jie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Rong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-e","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Long","family":"Duo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Kun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Li","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Lan","family":"Huan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.pupt.2023.102229_bib1","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1161\/CIRCRESAHA.120.316784","article-title":"Niacin attenuates pulmonary hypertension through H-PGDS in macrophages","volume":"127","author":"Jia","year":"2020","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.pupt.2023.102229_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.pupt.2023.102229_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.pupt.2023.102229_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bph.15016","article-title":"Current and future treatments of pulmonary arterial hypertension","volume":"178","author":"Sommer","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.pupt.2023.102229_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1089\/ham.2005.6.147","article-title":"Consensus statement on chronic and subacute high altitude diseases","volume":"6","author":"Le\u00f3n-Velarde","year":"2005","journal-title":"High Alt. Med. Biol."},{"issue":"24","key":"10.1016\/j.pupt.2023.102229_bib6","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.jacc.2011.06.068","article-title":"Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy","volume":"58","author":"Van De Veerdonk","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.pupt.2023.102229_bib7","doi-asserted-by":"crossref","first-page":"j5492","DOI":"10.1136\/bmj.j5492","article-title":"Pulmonary arterial hypertension: pathogenesis and clinical management","volume":"360","author":"Thenappan","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.pupt.2023.102229_bib8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3389\/fphar.2020.00687","article-title":"Sodium Tanshinone II Sulfonate A ameliorates hypoxia-induced pulmonary hypertension","volume":"11","author":"Bao","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.pupt.2023.102229_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.tetlet.2011.11.029","article-title":"LCZ696: a dual-acting sodium supramolecular complex","volume":"53","author":"Feng","year":"2012","journal-title":"Tetrahedron Lett."},{"issue":"10","key":"10.1016\/j.pupt.2023.102229_bib10","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jchf.2020.06.020","article-title":"Sacubitril\/valsartan: neprilysin inhibition 5 years after PARADIGM-HF","volume":"8","author":"Docherty","year":"2020","journal-title":"JACC heart fail"},{"issue":"5","key":"10.1016\/j.pupt.2023.102229_bib11","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/cvr\/cvaa200","article-title":"Additive protective effects of sacubitril\/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension","volume":"117","author":"Chaumais","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.pupt.2023.102229_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118877","article-title":"Sacubitril\/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism","volume":"266","author":"Liu","year":"2021","journal-title":"Life Sci."},{"issue":"11","key":"10.1016\/j.pupt.2023.102229_bib13","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.005819","article-title":"Treatment of pulmonary hypertension with angiotensin II receptor blocker and neprilysin inhibitor sacubitril\/valsartan","volume":"12","author":"Clements","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.pupt.2023.102229_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12931-020-01598-4","article-title":"Resistin-like molecule \u03b2 acts as a mitogenic factor in hypoxic pulmonary hypertension via the Ca(2+)-dependent PI3K\/Akt\/mTOR and PKC\/MAPK signaling pathways","volume":"22","author":"Tian","year":"2021","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2023.102229_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154329","article-title":"Luteolin ameliorates hypoxia-induced pulmonary hypertension via regulating HIF-2\u03b1-Arg-NO axis and PI3K-AKT-eNOS-NO signaling pathway","volume":"104","author":"Ji","year":"2022","journal-title":"Phytomedicine"},{"issue":"17","key":"10.1016\/j.pupt.2023.102229_bib16","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1111\/bph.15442","article-title":"Halofuginone, a promising drug for treatment of pulmonary hypertension","volume":"178","author":"Jain","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.pupt.2023.102229_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2478\/jtim-2019-0013","article-title":"NPS2390, a selective calcium-sensing receptor antagonist controls the phenotypic modulation of hypoxic human pulmonary arterial smooth muscle cells by regulating autophagy","volume":"7","author":"Peng","year":"2019","journal-title":"J Transl Int Med"},{"issue":"1","key":"10.1016\/j.pupt.2023.102229_bib18","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41392-021-00788-w","article-title":"Crosstalk between circRNAs and the PI3K\/AKT signaling pathway in cancer progression","volume":"6","author":"Xue","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"2","key":"10.1016\/j.pupt.2023.102229_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.pupt.2023.102229_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling","volume":"21","author":"Shorning","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.pupt.2023.102229_bib21","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1161\/CIRCULATIONAHA.114.006980","article-title":"Emerging concepts in the molecular basis of pulmonary arterial hypertension: Part II: neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension","volume":"131","author":"Maron","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2023.102229_bib22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13578-019-0348-1","article-title":"Angiotensin II receptor blocker LCZ696 attenuates cardiac remodeling through the inhibition of the ERK signaling pathway in mice with pregnancy-associated cardiomyopathy","volume":"9","author":"Wang","year":"2019","journal-title":"Cell Biosci."},{"issue":"1","key":"10.1016\/j.pupt.2023.102229_bib23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/emph\/eoaa052","article-title":"High-altitude pulmonary edema","volume":"9","author":"Woods","year":"2021","journal-title":"Evol Med Public Health"},{"key":"10.1016\/j.pupt.2023.102229_bib24","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.biopha.2018.11.058","article-title":"MicroRNA-150 relieves vascular remodeling and fibrosis in hypoxia-induced pulmonary hypertension","volume":"109","author":"Li","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.pupt.2023.102229_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pharmthera.2017.09.003","article-title":"Hypoxia inducible factor as a therapeutic target for atherosclerosis","volume":"183","author":"Jain","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"20","key":"10.1016\/j.pupt.2023.102229_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012656","article-title":"Inflammation in pulmonary hypertension and edema induced by hypobaric hypoxia exposure","volume":"23","author":"El Alam","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.pupt.2023.102229_bib27","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.chest.2016.10.030","article-title":"Solnatide demonstrates profound therapeutic activity in a rat model of pulmonary edema induced by acute hypobaric hypoxia and exercise","volume":"151","author":"Zhou","year":"2017","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.pupt.2023.102229_bib28","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/FJC.0000000000000662","article-title":"Effects of low-dose sacubitril\/valsartan on different stages of cardiac hypertrophy in salt-loaded hypertensive rats","volume":"73","author":"Hamano","year":"2019","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"7","key":"10.1016\/j.pupt.2023.102229_bib29","first-page":"959","article-title":"Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats","volume":"18","author":"Sun","year":"2014","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.pupt.2023.102229_bib30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pupt.2017.11.003","article-title":"Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats","volume":"48","author":"Shi","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"23","key":"10.1016\/j.pupt.2023.102229_bib31","first-page":"10549","article-title":"Effect of atorvastatin on pulmonary arterial hypertension in rats through PI3K\/AKT signaling pathway","volume":"23","author":"Wang","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.pupt.2023.102229_bib32","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3389\/fphys.2020.00774","article-title":"Novel therapeutic targets for hypoxia-related cardiovascular diseases: the role of HIF-1","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/j.pupt.2023.102229_bib33","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ebiom.2018.06.003","article-title":"IL-33 initiates vascular remodelling in hypoxic pulmonary hypertension by up-regulating HIF-1\u03b1 and VEGF expression in vascular endothelial cells","volume":"33","author":"Liu","year":"2018","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.pupt.2023.102229_bib34","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.pupt.2023.102229_bib35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/path.953","article-title":"Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis","volume":"195","author":"Tuder","year":"2001","journal-title":"J. Pathol."},{"issue":"6","key":"10.1016\/j.pupt.2023.102229_bib36","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1165\/ajrcmb.18.6.2980","article-title":"Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension","volume":"18","author":"Christou","year":"1998","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"9","key":"10.1016\/j.pupt.2023.102229_bib37","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1073\/pnas.080072497","article-title":"Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations","volume":"97","author":"Sutter","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pupt.2023.102229_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7256862","article-title":"LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac hypertrophy and fibrosis and cardiac lymphatic remodeling in transverse aortic constriction model mice","volume":"2020","author":"Ge","year":"2020","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.pupt.2023.102229_bib39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.yjmcc.2015.03.005","article-title":"Salidroside attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2a receptor related mitochondria-dependent apoptosis pathway","volume":"82","author":"Huang","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"2","key":"10.1016\/j.pupt.2023.102229_bib40","doi-asserted-by":"crossref","first-page":"H570","DOI":"10.1152\/ajpheart.01324.2007","article-title":"Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer","volume":"294","author":"Archer","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"25","key":"10.1016\/j.pupt.2023.102229_bib41","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1161\/CIRCULATIONAHA.117.028034","article-title":"Identification of microrna-124 as a major regulator of enhanced endothelial cell glycolysis in pulmonary arterial hypertension via PTBP1 (Polypyrimidine Tract Binding Protein) and pyruvate kinase M2","volume":"136","author":"Caruso","year":"2017","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.pupt.2023.102229_bib42","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1161\/CIRCULATIONAHA.117.028069","article-title":"Metabolic and proliferative state of vascular adventitial fibroblasts in pulmonary hypertension is regulated through a microRNA-124\/PTBP1 (Polypyrimidine Tract Binding Protein 1)\/pyruvate kinase muscle axis","volume":"136","author":"Zhang","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pupt.2023.102229_bib43","first-page":"641","article-title":"The IRE1\u03b1-XBP1 pathway function in hypoxia-induced pulmonary vascular remodeling, is upregulated by quercetin, inhibits apoptosis and partially reverses the effect of quercetin in PASMCs","volume":"11","author":"Cao","year":"2019","journal-title":"Am J Transl Res"},{"issue":"8","key":"10.1016\/j.pupt.2023.102229_bib44","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","article-title":"Mechanisms of disease: pulmonary arterial hypertension","volume":"8","author":"Schermuly","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.pupt.2023.102229_bib45","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijcard.2010.07.003","article-title":"Vascular remodeling in pulmonary arterial hypertension: multiple cancer-like pathways and possible treatment modalities","volume":"147","author":"Sakao","year":"2011","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"10.1016\/j.pupt.2023.102229_bib46","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3892\/mmr.2021.12041","article-title":"Sacubitril\/valsartan inhibits ox-LDL-induced MALAT1 expression, inflammation and apoptosis by suppressing the TLR4\/NF-\u03baB signaling pathway in HUVECs","volume":"23","author":"Bai","year":"2021","journal-title":"Mol. Med. Rep."},{"issue":"11","key":"10.1016\/j.pupt.2023.102229_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/antiox7110150","article-title":"Effects of Bcl-2\/Bcl-x(L) inhibitors on pulmonary artery smooth muscle cells","volume":"7","author":"Rybka","year":"2018","journal-title":"Antioxidants"},{"issue":"6","key":"10.1016\/j.pupt.2023.102229_bib48","first-page":"4984","article-title":"Formononetin attenuates monocrotaline-induced pulmonary arterial hypertension via inhibiting pulmonary vascular remodeling in rats","volume":"20","author":"Cai","year":"2019","journal-title":"Mol. Med. Rep."},{"issue":"4","key":"10.1016\/j.pupt.2023.102229_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22042144","article-title":"mTOR signaling in pulmonary vascular disease: pathogenic role and therapeutic target","volume":"22","author":"Babicheva","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.pupt.2023.102229_bib50","first-page":"308","article-title":"Osthole attenuates pulmonary arterial hypertension by the regulation of sphingosine 1-phosphate in rats","volume":"18","author":"Yao","year":"2020","journal-title":"Chin. J. Nat. Med."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109455392300041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109455392300041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:31:27Z","timestamp":1761082287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109455392300041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":50,"alternative-id":["S109455392300041X"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102229","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preventive effect of LCZ696 on hypoxic pulmonary hypertension in rats via regulating the PI3K\/AKT signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102229"}}